#United States #New York #Class Action #Levi & Korsinsky #ADMA Biologics

Levi & Korsinsky Issues Alert on ADMA Biologics Class Action

In a recent announcement, Levi & Korsinsky, LLP has reminded institutional investors of a class action lawsuit involving ADMA Biologics, Inc. The deadline for appointing a lead plaintiff in the case is fast approaching on August 10, 2026. Investors involved during the period from August 9, 2024 to March 25, 2026 are encouraged to evaluate their options amidst significant allegations targeting the company’s financial practices.

The Allegations

The class action has been filed on behalf of institutional investors, including pension funds and mutual funds, alleging that ADMA engaged in a channel stuffing scheme to artificially inflate revenue figures for its flagship product, ASCENIV. The reported revenue for ASCENIV reportedly soared from $92.6 million to $362.5 million within just two years, raising questions about the authenticity of these financial disclosures.

The complaint suggests that ADMA disclosed inflated revenue figures by concealing transactions with a related party distributor operating out of the company’s headquarters, thereby allegedly violating SEC regulations.

Joseph E. Levi, Esq., representing the firm, emphasized the vital role that institutional investors play in such securities class actions. Their involvement can significantly impact the litigation process and the potential for recovering losses.

Implications for Institutional Investors

For pension funds and asset managers holding ADMA shares during the Class Period, the potential exposure is substantial. It is crucial for these fiduciaries to assess whether they must investigate these allegations to protect the interests of their beneficiaries. Failing to do so could expose them to additional fiduciary liability.

Institutional investors are advised to carefully evaluate whether their investments in ADMA resulted in compensable losses due to the alleged fraudulent practices. Those with the largest documented losses should consider seeking appointment as lead plaintiff, which grants them direct oversight of the lawsuit's strategy and negotiations.

Claims made in the lawsuit assert violations under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5, asserting that misleading financial reporting practices and undisclosed related party dealings misled investors and distorted the company's financial standing.

Key Dates and Requirements

To participate, investors must be proactive. The deadline for applying for lead plaintiff status is August 10, 2026. All relevant documentation must be accurately prepared, including brokerage statements that verify purchase dates and share quantities.

Being appointed as a lead plaintiff does not require any additional financial commitment. Class actions operate on a contingency basis, meaning investors incur no upfront costs. This aspect is crucial for encouraging participation in class action suits, which typically span around two to four years from filing to resolution.

FAQs

• - Who can join the ADMA defendant lawsuit? Any investor who purchased shares within the stated Class Period and incurred losses may be eligible.
• - What if I sold my shares? The eligibility is based on the purchase date, so investors who sold at a loss during the period can still join the lawsuit.

Conclusion

The upcoming deadline necessitates urgency for institutional investors in evaluating their positions concerning ADMA Biologics. As allegations of misconduct mount, the opportunity for recovery simply cannot be overlooked. For further inquiries or assistance in evaluating claims, investors can reach out to Levi & Korsinsky, LLP by calling (212) 363-7500 or emailing [email protected].

This lawsuit serves as a reminder of the importance of due diligence in investment practices, particularly in the face of potential financial malpractices that can undermine investor trust and market integrity.

• ---

For comprehensive support and personalized advice, institutional investors are encouraged to consult directly with legal experts experienced in securities class action lawsuits.